General Information of Drug (ID: DM8WU3O)

Drug Name
Drug 2862277 Drug Info
Synonyms 2862277
Indication
Disease Entry ICD 11 Status REF
Acute lung injury NB32.3 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DM8WU3O

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
VB-111 DMX04CA Malignant glioma 2A00.0 Phase 3 [3]
AVX-470 DMAKD0I Inflammatory bowel disease DD72 Phase 1 [4]
GSK1995057 DMC14KV Adult respiratory distress syndrome CB00 Phase 1 [5]
Anti-IFN gamma DMXI185 Alopecia ED70 Terminated [4]
TNFR1 NAM DMPTQEG Multiple sclerosis 8A40 Investigative [2]
NM-9405 DMKMBSJ Rheumatoid arthritis FA20 Investigative [2]
TNFmab DM4T0ZF Rheumatoid arthritis FA20 Investigative [4]
ADS-0101 DMP7IS0 Chronic obstructive pulmonary disease CA22 Investigative [2]
Recombinant human TNF receptor DMLYQWV Arthritis FA20 Investigative [4]
TNFcept DMAGI7K Rheumatoid arthritis FA20 Investigative [4]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tumor necrosis factor receptor type I (TNF-R1) TTG043C TNR1A_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT02221037) Study of GSK2862277 in Subjects Undergoing Oesophagectomy Surgery. U.S. National Institutes of Health.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1870).
3 Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors.Clin Cancer Res.2013 Jul 15;19(14):3996-4007.
4 Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65.
5 Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-alpha receptor 1. J Clin Immunol. 2013 Oct;33(7):1192-203.